# Anticancer Activity of 2,3′-Dihydroxy-5′-Methoxystilbene Against NSCLC Cell Lines Through AKT-Dependent Mechanisms: A Comprehensive In Vitro and Computational Analysis

**Authors:** Phisit Pouyfung, Nonthalert Lertnitikul, Noriyoshi Ogino, Achitphol Chookaew, Varisa Pongrakhananon, Piriya Chonsut, Natthaporn Sueangoen, Suwichak Chaisit

PMC · DOI: 10.3390/ijms27020719 · 2026-01-10

## TL;DR

A new compound shows strong anticancer effects on lung cancer cells by targeting the AKT pathway and has low toxicity to normal cells.

## Contribution

The study identifies a selective AKT-targeting stilbene with context-dependent chemosensitizing activity in NSCLC cells.

## Key findings

- The compound significantly reduced the viability of NSCLC cells with minimal toxicity to normal fibroblasts.
- It induced apoptosis and suppressed proliferation, migration, and colony formation in a dose-dependent manner.
- Molecular studies showed AKT-dependent activity, with reduced p-AKT and p-GSK3β levels in treated cells.

## Abstract

Lung cancer remains a major clinical challenge, with therapy resistance in non-small-cell lung cancer (NSCLC) driving the search for novel selective agents. This study demonstrates that 2,3′-dihydroxy-5′-methoxystilbene exhibits significant anticancer activity in NSCLC cell lines (A549, H23, and H460) while displaying substantially lower toxicity toward normal NIH/3T3 fibroblasts. The compound reduced the viability of H23 and H460 cells after 48 h. (IC50: 23.39 ± 3.27 μM and 24.20 ± 2.61 μM, respectively), with NIH/3T3 cells remaining comparatively resistant (IC50 > 100 μM). At 25 μM, it suppressed proliferation by approximately 40% in H23, 30% in H460, and 20% in A549 cells, and dose-dependently impaired colony formation and migration, leading to near-complete migration arrest in H460 cells. Apoptosis induction peaked at 19% in H23, 17% in H460, and 8% in A549 cells at 25 μM. Mechanistic studies and molecular modeling revealed AKT-dependent activity, with decreased p-AKT and p-GSK3β levels (0.70 and 0.75 in H23; 0.65 and 0.70 in H460 at 25 μM), without changes in total protein expression. Combination treatment with cisplatin yielded synergistic effects in A549 (CI = 0.83) and H460 (CI = 0.94) cells, but antagonistic effects in H23 cells (CI = 1.32). These findings identify 2,3′-dihydroxy-5′-methoxystilbene as a selective AKT-targeting stilbene with promising anticancer potential and context-dependent chemosensitizing activity in NSCLC cells.

## Linked entities

- **Genes:** AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932]
- **Chemicals:** 2,3′-dihydroxy-5′-methoxystilbene (PubChem CID 129846245), cisplatin (PubChem CID 5460033)
- **Diseases:** non-small-cell lung cancer (MONDO:0005233), lung cancer (MONDO:0005138)

## Full-text entities

- **Genes:** GSK3B (glycogen synthase kinase 3 beta) [NCBI Gene 2932], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207] {aka AKT, PKB, PKB-ALPHA, PRKBA, RAC, RAC-ALPHA}
- **Diseases:** NSCLC (MESH:D002289), toxicity (MESH:D064420), Lung cancer (MESH:D008175)
- **Chemicals:** cisplatin (MESH:D002945), stilbene (MESH:D013267), 2,3'-Dihydroxy-5'-Methoxystilbene (-)

## Figures

14 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12840911/full.md

---
Source: https://tomesphere.com/paper/PMC12840911